The principal mission of the Institut Bordet Department of Surgery is the surgical treatment of cancerous diseases.
More specifically, our surgeons strive to:
- offer leading-edge surgical techniques in the treatment of cancer;
- integrate surgery into global cancer treatment;
- encourage approaches combining surgery and other treatments such as chemotherapy, radiotherapy, nuclear medicine, interventional radiology, immunotherapy, etc;
- promote research and develop innovative treatments;
- collaborate at national and international levels with other cancer centres;
- teach surgery to medical students and future surgeons;
- train surgeons specifically in oncological surgery.
The Institut Bordet Department of Surgery comprises 6 specific fields:
- Cervicofacial and Thoracic Surgery
- Digestive Surgery
- Breast and Pelvic Surgery
- Bone and Connective Tissue Tumour Surgery
- Cancer Reconstructive Surgery
- Skin Tumour Surgery.
In each discipline, the Department of Surgery develops an integrated and individualised approach using leading-edge techniques and technologies.
- In individualised treatment, the aim is to adapt the therapeutic options to each patient. This means that surgical treatment is adapted to meet the specific characteristics of the cancer and the particular circumstances and requests of patients.
- Surgical techniques evolve. New treatments are regularly being developed. Each field of surgery participates in advances in its discipline, both from the viewpoint of diagnostic methods and the treatments themselves. The Institut Bordet follows these developments very closely. Our surgeons train in the latest techniques and the Department of Surgery regularly acquires the new equipment and instruments needed to develop new treatment options.
- Surgical treatments are always integrated into global patient care as part of a multidisciplinary collaboration. The Department and the Hospital are organised to help optimise these collaborations between the different surgical disciplines and with all the departments involved in patient care and treatment. In each field, treatments are discussed on a weekly basis at multidisciplinary cancer care meetings (CMOs) involving different specialist doctors.
The Institut Bordet Department of Surgery is involved in teaching in the Faculty of Medicine, on different inter-university diploma courses and in the Hautes Écoles nursing colleges.
The Department of Surgery teaches surgery to students from the Faculty of Medicine and, in particular, the specificities of oncological surgery. This teaching is also delivered to students and young doctors coming from abroad.
Research projects
Project 1
Study of the contribution of Fluorescence Imaging in the diagnosis and staging of cancer.
- Collaborations : Group R&D for the Clinical Application of Fluorescence Imaging, Institut Jules Bordet
- Funding : Les Amis de l'Institut Bordet
Project 2
Study of immunogenicity and immune response in hepatocellular carcinoma.
- Collaborations : Institut d’Immunologie médicale (IMI), ULB, Institut De Duve (UCL).
- Funding : FNRS, Les Amis de l'Institut Bordet
Project 3
Identification of oligometastatic profiles in colorectal cancer: creation of a multidisciplinary platform.
- Collaborations : Medical Oncology Department, Anatomical Pathology Department, Nuclear Medicine Department, BCTL - Breast Cancer Translational Research Lab, Institut Jules Bordet
Project 4
Evaluation of metabolic and pathological response after radio-chemotherapy and immunotherapy in advanced oesophageal and oesogastric junction cancers (ARTemIS)
- Collaborations : Medical Oncology Department, Anatomical Pathology Department, Nuclear Medicine Department, Institut Jules Bordet
Our team
Head of Department
Prof Vincent Donckier
Digestive Surgery
Pr Gabriel Liberale, Head of Clinic
Pr Vincent Donckier
Dr Fikri Bouazza
Pr Issam El Nakadi
Dr Florin Catalin Pop
Pr Jean Van de Stadt
Cervicofacial and Thoracic Surgery
Dr Antoine Digonnet, Head of Clinic
Dr Esther Willemse
Dr Marie Quiriny
Dr Samuel Lipski (ENT specialist)
Dr Cécile Dekeyser (ENT specialist)
Pr Guy Andry, Honorary Professor of Surgery
Breast and Pelvic Surgery
Dr Isabelle Veys, Head of Clinic
Dr Danièle Noterman
Dr Filip De Neubourg
Dr Mirela Roman
Pr Jean Marie Nogaret
Dr Florin Catalin Pop
Cancer Reconstructive Surgery
Dr Frédéric Urbain, Head of Clinic
Dr Simona Brondello
Dr Dimitri Tsepelidis
Dr Marta Misani
Skin Tumour Surgery
Dr François Sales, Head of Clinic
Dr Marie Quiriny
Bone and Connective Tissue Tumour Surgery
Dr Felix Shumelinsky, Head of Clinic
Dr Bilal Kapanci
Pr Michael Gebhart
Senior Nurses – In-patient unit
Ingrid Bruyns
Fabienne Van Ginderachter
Secretariat
Marylène Boulet
Laurence Wanet
13/05/2020
Scientific publications
Cross-Talk Between Mesenchymal Stromal Cells (MSCs) and Endothelial Progenitor Cells (EPCs) in Bone Regeneration.
Authors : Bouland C, Philippart P, Dequanter D, Corrillon F, Loeb I, Bron D, Lagneaux L, Meuleman N
Year : 2021
Journal : Front Cell Dev Biol
Volume : 9
Pages : 674084
The histological growth pattern and the clinico-metabolic characteristics accurately predict the outcome in patients undergoing surgery for colorectal liver metastases - Belgian Group for Digestive Oncology (BGDO).
Authors : Bohlok A, Derijckere ID, Azema H, Lucidi V, Vankerckhove S, Hendlisz A, Laethem JLV, Goldman S, Flamen P, Larsimont D, Demetter P, Dirix L, Vermeulen P, Donckier V
Year : 2021
Journal : Ann Hepatobiliary Pancreat Surg
Volume : 25
Pages : S63
Buschke-Löwenstein tumor in a human immunodeficiency virus-positive patient: a case report and short literature review.
Authors : Ledouble V, Sclafani F, Hendlisz A, Gomez Galdon M, Liberale G
Year : 2021
Journal : Acta Gastroenterol Belg
Volume : 84
Pages : 343-345
Is Endovascular Retroperitoneoscopic Aortobifemoral Bypass a Reasonable Alternative to Transperitoneal Open Surgery for Treatment of Severe Aorto-Iliac Occlusive Lesions? A Retrospective Comparative Analysis.
Authors : Segers B, Solari L, Ferrera J, Sosnowski M, Wautrecht JC, Donckier V
Year : 2021
Journal : Eur J Vasc Endovasc Surg
Volume : 62
Pages : 489-490
MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways.
Authors : Augenlicht A, Saiselet M, Decaussin-Petrucci M, Andry G, Dumont JE, Maenhaut C
Year : 2021
Journal : Oncotarget
Volume : 12
Pages : 1587-1599
